Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls

By Yahoo! Finance   |   1 month ago
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls

Incyte Corporation announced positive results from the Phase 3 STOP-HS trials of povorcitinib for treating hidradenitis suppurativa, a painful skin condition. The studies showed efficacy and safety with a significant reduction in abscesses and nodules.

Read More

Did you find this insightful?